Oral Contraceptives
Aubra EQ®
(levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg
Compares to
ALESSE®*, Afirmelle™, Aviane® 28, Falmina™, and Orsythia®
WARNING
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Chateal EQ®
(levonorgestrel and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg
Compares to
Nordette®-28*, Portia®, Altavera®, Kurvelo™, and Marlissa®
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including levonorgestrel and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke.
Cyred EQ®
(desogestrel and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg
Compares to
Ortho-Cept®*, Desogen®*, Isibloom®, Emoquette®, Enskyce™, and Reclipsen™
WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including Cyred EQ, should not be used by women over 35 years of age and smoke.
Jasmiel®
(drospirenone and ethinyl estradiol tablets, USP) 3 mg/0.02 mg
Compares to
Yaz®, Gianvi™, Loryna®, Lo-Zumandimine™, and Nikki™
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke.
Lyleq®
(norethindrone tablets, USP) 0.35 mg
Compares to
NOR-QD®, Camila®, Heather®, and Incassia®
WARNING
Cigarette smoking greatly increases the possibility of suffering heart attacks and strokes. Women who use oral contraceptives are strongly advised not to smoke.
Tarina® 24 Fe
(norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) 1 mg/20 mcg and 75 mg
Compares to
Loestrin® 24 Fe*, Junel® Fe 24, Aurovela® 24 Fe, Blisovi™ 24 Fe, and Larin™ 24 Fe
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.
Tarina Fe 1/20 EQ®
(norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) 1 mg/20 mcg and 75 mg
Compares to
Loestrin® Fe 1/20, Junel® Fe 1/20, Blisovi™ Fe 1/20, Larin™ Fe 1/20, Microgestin® Fe 1/20, and Tarina® Fe 1/20
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Tarina 24 Fe 1/20 EQ, are contraindicated in women who are over 35 years of age and smoke.
Tri-VyLibra®
(norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.250 mg/0.035 mg
Compares to
Ortho Tri-Cyclen®*, Tri-Estarylla®, Tri-Linyah®, Tri-Previfem®, and Tri-Sprintec®
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke.
Tri-VyLibra® Lo
(norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg
Compares to
Ortho Tri-Cyclen® Lo*, Tri-Lo-Estarylla®, Tri-Lo-Marzia™, Tri-Lo-Mili®, and Tri-Lo-Sprintec®
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke.
VyLibra®
(norgestimate and ethinyl estradiol tablets, USP) 0.250 mg/0.035 mg
Compares to
Ortho-Cyclen-28®*, Estarylla®, Mili®, Mono-Linyah™, Previfem®, and Sprintec®
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke.
